Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Erasca's Pre-Tax Income for the
three
months ended in Mar. 2024 was $-35.02 Mil. Erasca's Revenue for the
three
months ended in Mar. 2024 was $0.00 Mil. Therefore, Erasca's pretax margin for the quarter that ended in Mar. 2024 was %.
The historical rank and industry rank for Erasca's Pretax Margin % or its related term are showing as below:
ERAS's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.03 * Ranked among companies with meaningful Pretax Margin % only.
Erasca Pretax Margin % Historical Data
The historical data trend for Erasca's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Erasca's Pretax Margin %
For the Biotechnology subindustry, Erasca's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erasca's Pretax Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Erasca's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Erasca's Pretax Margin % falls into.
Erasca Pretax Margin % Calculation
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
Erasca's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Erasca (NAS:ERAS) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Erasca Pretax Margin % Related Terms
Thank you for viewing the detailed overview of Erasca's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERAS has been successfully added to your 